NBIX
Neurocrine Biosciences, Inc.
Price Chart
Latest Quote
$137.63
Current Price| Previous Close | $136.06 |
| Open | $135.33 |
| Day High | $137.95 |
| Day Low | $135.00 |
| Volume | 900,332 |
Stock Information
| Shares Outstanding | 99.71M |
| Total Debt | $479.70M |
| Cash Equivalents | $1.11B |
| Revenue | $2.68B |
| Net Income | $428.00M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $13.72B |
| P/E Ratio | 32.85 |
| EPS (TTM) | $4.19 |
| Exchange | NMS |
📊 Custom Metrics & Score
Score: 28/42| Debt to Equity | 0.18 |
| Debt to Earnings | 0.20 |
| Current Ratio | 3.40 |
| Quick Ratio | 3.06 |
| Avg Revenue Growth | 26.95% |
| Profit Margin | 14.49% |
| Return on Equity | 13.18% |
| Avg FCF Growth | 34.76% |
| FCF Yield | 4.06% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $137.63 | 904,851 |
| 2026-01-30 | $136.06 | 1,035,400 |
| 2026-01-29 | $137.96 | 928,500 |
| 2026-01-28 | $134.66 | 934,800 |
| 2026-01-27 | $133.89 | 582,400 |
| 2026-01-26 | $134.51 | 925,300 |
| 2026-01-23 | $136.18 | 1,159,700 |
| 2026-01-22 | $137.37 | 800,400 |
| 2026-01-21 | $135.41 | 927,300 |
| 2026-01-20 | $134.54 | 1,057,100 |
| 2026-01-16 | $132.39 | 1,023,400 |
| 2026-01-15 | $133.35 | 891,000 |
| 2026-01-14 | $135.33 | 1,078,900 |
| 2026-01-13 | $132.26 | 1,161,200 |
| 2026-01-12 | $132.66 | 1,923,000 |
| 2026-01-09 | $135.79 | 1,419,300 |
| 2026-01-08 | $135.57 | 1,568,500 |
| 2026-01-07 | $140.62 | 1,289,100 |
| 2026-01-06 | $137.35 | 1,118,400 |
| 2026-01-05 | $135.99 | 1,614,600 |
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
📰 Latest News
Is Neurocrine Biosciences (NBIX) Offering Value After Recent Share Price Weakness
Simply Wall St. • 2026-01-28T05:07:21Z
Assessing Neurocrine Biosciences (NBIX) Valuation After New Phase 2 VMAT2 Tardive Dyskinesia Trial Launch
Simply Wall St. • 2026-01-27T13:13:54Z
Can Neurocrine (NBIX) Keep the Earnings Surprise Streak Alive?
Zacks • 2026-01-22T17:10:05Z
Reassessing Neurocrine Biosciences (NBIX) After Recent Share Price Weakness
Simply Wall St. • 2026-01-09T13:11:38Z
How Eli Lilly's Plan To Buy Ventyx For $1.2 Billion Could Benefit Neumora, Neurocrine
Investor's Business Daily • 2026-01-08T21:10:11Z
Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Coinbase Global, Digital Realty Trust, Intuit, Reddit, Roku, Tyler Technologies, and More
24/7 Wall St. • 2026-01-08T13:09:47Z
Exploring Three High Growth Tech Stocks In The US Market
Simply Wall St. • 2025-12-17T17:38:28Z
Leading Drug Stock Fights To Regain Buy Point At Key Resistance Level
Investor's Business Daily • 2025-12-05T13:00:16Z
Three Stocks That Could Be Undervalued By Market Estimates In December 2025
Simply Wall St. • 2025-12-05T11:37:57Z
Neurocrine Biosciences (NBIX): Revisiting Valuation Following Decade-Long VMAT2 Review Publication
Simply Wall St. • 2025-11-28T09:09:21Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $34,000,000 | $39,700,000 | $23,200,000 | $14,300,000 |
| Cost Of Revenue | $34,000,000 | $39,700,000 | $23,200,000 | $14,300,000 |
| Total Revenue | $2,355,300,000 | $1,887,100,000 | $1,488,700,000 | $1,133,500,000 |
| Operating Revenue | $2,355,300,000 | $1,887,100,000 | $1,488,700,000 | $1,133,500,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $126,600,000 | $4,600,000 | $7,100,000 | $25,800,000 |
| Total Expenses | $1,772,300,000 | $1,492,300,000 | $1,239,700,000 | $925,700,000 |
| Other Income Expense | $-61,400,000 | $-115,500,000 | $-39,200,000 | $-80,600,000 |
| Net Non Operating Interest Income Expense | $-35,600,000 | $52,800,000 | $4,100,000 | $-25,800,000 |
| Interest Expense Non Operating | $126,600,000 | $4,600,000 | $7,100,000 | $25,800,000 |
| Operating Expense | $1,738,300,000 | $1,452,600,000 | $1,216,500,000 | $911,400,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $341,300,000 | $249,700,000 | $154,500,000 | $89,600,000 |
| Net Interest Income | $-35,600,000 | $52,800,000 | $4,100,000 | $-25,800,000 |
| Interest Income | $91,000,000 | $52,800,000 | $4,100,000 | - |
| Normalized Income | $384,418,971 | $336,542,367 | $182,814,165 | $160,820,513 |
| Net Income From Continuing And Discontinued Operation | $341,300,000 | $249,700,000 | $154,500,000 | $89,600,000 |
| Total Operating Income As Reported | $570,500,000 | $250,900,000 | $249,000,000 | $102,500,000 |
| Net Income Common Stockholders | $341,300,000 | $249,700,000 | $154,500,000 | $89,600,000 |
| Net Income | $341,300,000 | $249,700,000 | $154,500,000 | $89,600,000 |
| Net Income Including Noncontrolling Interests | $341,300,000 | $249,700,000 | $154,500,000 | $89,600,000 |
| Net Income Continuous Operations | $341,300,000 | $249,700,000 | $154,500,000 | $89,600,000 |
| Pretax Income | $486,000,000 | $332,100,000 | $213,900,000 | $101,400,000 |
| Special Income Charges | $-14,700,000 | $-143,900,000 | $-70,000,000 | $-105,300,000 |
| Interest Income Non Operating | $91,000,000 | $52,800,000 | $4,100,000 | - |
| Operating Income | $583,000,000 | $394,800,000 | $249,000,000 | $207,800,000 |
| Gross Profit | $2,321,300,000 | $1,847,400,000 | $1,465,500,000 | $1,119,200,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $3.29 | $2.47 | $1.56 | $0.92 |
| Basic EPS | $3.40 | $2.56 | $1.61 | $0.95 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $-18,281,029 | $-28,657,633 | $-10,885,835 | $-9,379,487 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $701,100,000 | $531,600,000 | $303,800,000 | $218,700,000 |
| Total Unusual Items | $-61,400,000 | $-115,500,000 | $-39,200,000 | $-80,600,000 |
| Total Unusual Items Excluding Goodwill | $-61,400,000 | $-115,500,000 | $-39,200,000 | $-80,600,000 |
| Reconciled Depreciation | $27,100,000 | $21,300,000 | $15,600,000 | $10,900,000 |
| EBITDA (Bullshit earnings) | $639,700,000 | $416,100,000 | $264,600,000 | $138,100,000 |
| EBIT | $612,600,000 | $394,800,000 | $249,000,000 | $127,200,000 |
| Diluted Average Shares | $103,700,000 | $101,000,000 | $98,900,000 | $97,900,000 |
| Basic Average Shares | $100,400,000 | $97,700,000 | $95,800,000 | $94,600,000 |
| Diluted NI Availto Com Stockholders | $341,300,000 | $249,700,000 | $154,500,000 | $89,600,000 |
| Tax Provision | $144,700,000 | $82,400,000 | $59,400,000 | $11,800,000 |
| Other Special Charges | $14,700,000 | $143,900,000 | $70,000,000 | $105,300,000 |
| Gain On Sale Of Security | $-46,700,000 | $28,400,000 | $30,800,000 | $24,700,000 |
| Research And Development | $731,100,000 | $565,000,000 | $463,800,000 | $328,100,000 |
| Selling General And Administration | $1,007,200,000 | $887,600,000 | $752,700,000 | $583,300,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $2,553,200,000 | $2,196,500,000 | $1,670,600,000 | $1,374,000,000 |
| Total Assets | $3,718,700,000 | $3,251,400,000 | $2,368,700,000 | $2,072,500,000 |
| Total Non Current Assets | $1,994,000,000 | $1,644,400,000 | $915,200,000 | $1,099,700,000 |
| Other Non Current Assets | $15,500,000 | $49,600,000 | $25,000,000 | $4,400,000 |
| Non Current Deferred Assets | $485,700,000 | $362,600,000 | $305,900,000 | $315,100,000 |
| Non Current Deferred Taxes Assets | $485,700,000 | $362,600,000 | $305,900,000 | $315,100,000 |
| Investmentin Financial Assets | $864,300,000 | $849,400,000 | $401,500,000 | $624,400,000 |
| Goodwill And Other Intangible Assets | $36,500,000 | $35,500,000 | $37,200,000 | $0 |
| Other Intangible Assets | $36,500,000 | $35,500,000 | $37,200,000 | - |
| Current Assets | $1,724,700,000 | $1,607,000,000 | $1,453,500,000 | $972,800,000 |
| Other Current Assets | $112,100,000 | $97,800,000 | $79,100,000 | $45,500,000 |
| Inventory | $57,400,000 | $38,300,000 | $35,100,000 | $30,500,000 |
| Receivables | $479,100,000 | $439,300,000 | $350,000,000 | $185,500,000 |
| Accounts Receivable | $479,100,000 | $439,300,000 | $350,000,000 | $185,500,000 |
| Cash Cash Equivalents And Short Term Investments | $1,076,100,000 | $1,031,600,000 | $989,300,000 | $711,300,000 |
| Cash And Cash Equivalents | $233,000,000 | $251,100,000 | $262,900,000 | $340,800,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $455,100,000 | $428,400,000 | $262,900,000 | $440,400,000 |
| Long Term Debt And Capital Lease Obligation | $455,100,000 | $258,300,000 | $93,500,000 | $440,400,000 |
| Current Debt And Capital Lease Obligation | - | $170,100,000 | $169,400,000 | - |
| Current Debt | - | $170,100,000 | $169,400,000 | - |
| Other Current Borrowings | - | $170,100,000 | $169,400,000 | - |
| Long Term Debt | - | - | - | $335,100,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $1,129,000,000 | $1,019,400,000 | $660,900,000 | $698,500,000 |
| Total Non Current Liabilities Net Minority Interest | $621,300,000 | $364,600,000 | $123,200,000 | $452,700,000 |
| Other Non Current Liabilities | $5,500,000 | $10,300,000 | $9,900,000 | $12,300,000 |
| Tradeand Other Payables Non Current | $160,700,000 | $96,000,000 | $19,800,000 | - |
| Current Liabilities | $507,700,000 | $654,800,000 | $537,700,000 | $245,800,000 |
| Other Current Liabilities | $46,000,000 | $35,900,000 | $20,700,000 | $20,000,000 |
| Payables And Accrued Expenses | $210,000,000 | $223,300,000 | $142,900,000 | $112,500,000 |
| Payables | $110,000,000 | $133,300,000 | $76,300,000 | $51,500,000 |
| Accounts Payable | $110,000,000 | $133,300,000 | $67,300,000 | $51,500,000 |
| Total Tax Payable | - | $24,400,000 | $9,000,000 | - |
| Income Tax Payable | - | $24,400,000 | $9,000,000 | - |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $2,589,700,000 | $2,232,000,000 | $1,707,800,000 | $1,374,000,000 |
| Total Equity Gross Minority Interest | $2,589,700,000 | $2,232,000,000 | $1,707,800,000 | $1,374,000,000 |
| Stockholders Equity | $2,589,700,000 | $2,232,000,000 | $1,707,800,000 | $1,374,000,000 |
| Gains Losses Not Affecting Retained Earnings | $5,800,000 | $7,000,000 | $-7,900,000 | $-1,700,000 |
| Other Equity Adjustments | $5,800,000 | $7,000,000 | $-7,900,000 | $-1,700,000 |
| Retained Earnings | $29,200,000 | $-157,100,000 | $-406,800,000 | $-635,800,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $99,400,000 | $98,700,000 | $96,500,000 | $94,900,000 |
| Share Issued | $99,400,000 | $98,700,000 | $96,500,000 | $94,900,000 |
| Tangible Book Value | $2,553,200,000 | $2,196,500,000 | $1,670,600,000 | $1,374,000,000 |
| Invested Capital | $2,589,700,000 | $2,402,100,000 | $1,877,200,000 | $1,709,100,000 |
| Working Capital | $1,217,000,000 | $952,200,000 | $915,800,000 | $727,000,000 |
| Capital Lease Obligations | $455,100,000 | $258,300,000 | $93,500,000 | $105,300,000 |
| Total Capitalization | $2,589,700,000 | $2,232,000,000 | $1,707,800,000 | $1,709,100,000 |
| Additional Paid In Capital | $2,554,600,000 | $2,382,000,000 | $2,122,400,000 | $2,011,400,000 |
| Capital Stock | $100,000 | $100,000 | $100,000 | $100,000 |
| Common Stock | $100,000 | $100,000 | $100,000 | $100,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $455,100,000 | $258,300,000 | $93,500,000 | $105,300,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $107,500,000 | $86,200,000 | $72,800,000 | $50,600,000 |
| Current Provisions | $144,200,000 | $139,300,000 | $131,900,000 | $62,700,000 |
| Current Accrued Expenses | $100,000,000 | $90,000,000 | $66,600,000 | $61,000,000 |
| Investments And Advances | $864,300,000 | $849,400,000 | $401,500,000 | $624,400,000 |
| Available For Sale Securities | $864,300,000 | $849,400,000 | $401,500,000 | $624,400,000 |
| Net PPE | $592,000,000 | $347,300,000 | $145,600,000 | $155,800,000 |
| Accumulated Depreciation | $-106,500,000 | $-83,000,000 | $-66,300,000 | $-51,900,000 |
| Gross PPE | $698,500,000 | $430,300,000 | $211,900,000 | $207,700,000 |
| Leases | $35,900,000 | $38,100,000 | $37,900,000 | $34,900,000 |
| Other Properties | $605,100,000 | $356,100,000 | $145,800,000 | $148,800,000 |
| Machinery Furniture Equipment | $57,500,000 | $36,100,000 | $28,200,000 | $24,000,000 |
| Properties | $0 | $0 | $0 | $0 |
| Inventories Adjustments Allowances | $0 | $-5,200,000 | $0 | - |
| Finished Goods | $12,800,000 | $12,300,000 | $17,500,000 | $15,700,000 |
| Work In Process | $10,900,000 | $9,700,000 | $5,600,000 | $3,600,000 |
| Raw Materials | $33,700,000 | $21,500,000 | $12,000,000 | $11,200,000 |
| Other Short Term Investments | $843,100,000 | $780,500,000 | $726,400,000 | $370,500,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $557,200,000 | $361,600,000 | $322,900,000 | $233,100,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $595,400,000 | $389,900,000 | $339,400,000 | $256,500,000 |
| Cash Flow From Continuing Operating Activities | $595,400,000 | $389,900,000 | $339,400,000 | $256,500,000 |
| Operating Gains Losses | - | - | $70,000,000 | - |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-38,200,000 | $-28,300,000 | $-16,500,000 | $-23,400,000 |
| Investing Cash Flow | $-126,800,000 | $-467,100,000 | $-177,100,000 | $-130,200,000 |
| Cash Flow From Continuing Investing Activities | $-126,800,000 | $-467,100,000 | $-177,100,000 | $-130,200,000 |
| Capital Expenditure Reported | $-38,200,000 | $-28,300,000 | $-16,500,000 | $-23,400,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repurchase Of Capital Stock | $-300,000,000 | $0 | $0 | - |
| Financing Cash Flow | $-486,700,000 | $65,300,000 | $-234,300,000 | $27,400,000 |
| Cash Flow From Continuing Financing Activities | $-486,700,000 | $65,300,000 | $-234,300,000 | $27,400,000 |
| Net Common Stock Issuance | $-300,000,000 | $0 | $0 | - |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-308,800,000 | $0 | $-279,000,000 | $-100,000 |
| Interest Paid Supplemental Data | $1,600,000 | $3,800,000 | $6,600,000 | $8,600,000 |
| Income Tax Paid Supplemental Data | $217,500,000 | $51,500,000 | $14,400,000 | $5,100,000 |
| End Cash Position | $241,000,000 | $259,100,000 | $270,700,000 | $344,000,000 |
| Beginning Cash Position | $259,100,000 | $270,700,000 | $344,000,000 | $190,300,000 |
| Effect Of Exchange Rate Changes | $0 | $300,000 | $-1,300,000 | $0 |
| Changes In Cash | $-18,100,000 | $-11,900,000 | $-72,000,000 | $153,700,000 |
| Proceeds From Stock Option Exercised | $122,100,000 | $65,300,000 | $44,700,000 | $27,500,000 |
| Common Stock Payments | $-300,000,000 | $0 | $0 | - |
| Net Issuance Payments Of Debt | $-308,800,000 | $0 | $-279,000,000 | $-100,000 |
| Net Short Term Debt Issuance | $-308,800,000 | $0 | $-279,000,000 | $-100,000 |
| Short Term Debt Payments | $-308,800,000 | $0 | $-279,000,000 | $-100,000 |
| Net Investment Purchase And Sale | $-88,600,000 | $-438,800,000 | $-117,900,000 | $-106,800,000 |
| Sale Of Investment | $967,500,000 | $972,400,000 | $511,000,000 | $697,900,000 |
| Purchase Of Investment | $-1,056,100,000 | $-1,411,200,000 | $-628,900,000 | $-804,700,000 |
| Net Business Purchase And Sale | $0 | $0 | $-42,700,000 | $0 |
| Purchase Of Business | $0 | $0 | $-42,700,000 | $0 |
| Change In Working Capital | $-19,200,000 | $28,200,000 | $-67,400,000 | $16,700,000 |
| Change In Other Working Capital | $10,700,000 | $47,800,000 | $-17,200,000 | $-9,200,000 |
| Change In Payables And Accrued Expense | $29,000,000 | $64,300,000 | $114,600,000 | $56,800,000 |
| Change In Inventory | $-19,100,000 | $5,400,000 | $-2,600,000 | $-2,500,000 |
| Change In Receivables | $-39,800,000 | $-89,300,000 | $-162,200,000 | $-28,400,000 |
| Changes In Account Receivables | $-39,800,000 | $-89,300,000 | $-162,200,000 | $-28,400,000 |
| Other Non Cash Items | $162,900,000 | $-200,000 | $71,600,000 | $14,300,000 |
| Stock Based Compensation | $195,500,000 | $194,300,000 | $173,100,000 | $134,200,000 |
| Unrealized Gain Loss On Investment Securities | $37,100,000 | $-28,400,000 | $-30,800,000 | $-20,900,000 |
| Amortization Of Securities | $-26,200,000 | $-18,300,000 | $3,700,000 | $7,400,000 |
| Deferred Tax | $-123,100,000 | $-56,700,000 | $19,100,000 | $4,300,000 |
| Deferred Income Tax | $-123,100,000 | $-56,700,000 | $19,100,000 | $4,300,000 |
| Depreciation Amortization Depletion | $27,100,000 | $21,300,000 | $15,600,000 | $10,900,000 |
| Depreciation And Amortization | $27,100,000 | $21,300,000 | $15,600,000 | $10,900,000 |
| Amortization Cash Flow | $3,600,000 | $3,500,000 | $500,000 | $0 |
| Amortization Of Intangibles | $3,600,000 | $3,500,000 | $500,000 | $0 |
| Depreciation | $23,500,000 | $17,800,000 | $15,100,000 | $10,900,000 |
| Net Income From Continuing Operations | $341,300,000 | $249,700,000 | $154,500,000 | $89,600,000 |
| Net Long Term Debt Issuance | - | $0 | $-279,000,000 | $-100,000 |
| Long Term Debt Payments | - | $0 | $-279,000,000 | $-100,000 |
| Net PPE Purchase And Sale | - | - | - | $-23,400,000 |
| Purchase Of PPE | - | - | - | $-23,400,000 |